333 related articles for article (PubMed ID: 32459456)
1. Proteomic research and diagnosis in bladder cancer: state of the art review.
Wilson JL; Antoniassi MP; Lopes PI; Azevedo H
Int Braz J Urol; 2021; 47(3):503-514. PubMed ID: 32459456
[TBL] [Abstract][Full Text] [Related]
2. Urinary Biomarkers for Diagnosis of Bladder Cancer: A Systematic Review and Meta-analysis.
Chou R; Gore JL; Buckley D; Fu R; Gustafson K; Griffin JC; Grusing S; Selph S
Ann Intern Med; 2015 Dec; 163(12):922-31. PubMed ID: 26501851
[TBL] [Abstract][Full Text] [Related]
3. Surveillance for recurrent bladder cancer using a point-of-care proteomic assay.
Grossman HB; Soloway M; Messing E; Katz G; Stein B; Kassabian V; Shen Y
JAMA; 2006 Jan; 295(3):299-305. PubMed ID: 16418465
[TBL] [Abstract][Full Text] [Related]
4. Urinary markers in the everyday diagnosis of bladder cancer.
Dal Moro F; Valotto C; Guttilla A; Zattoni F
Urologia; 2013; 80(4):265-75. PubMed ID: 24419920
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the BTA stat test with voided urine cytology and bladder wash cytology in the diagnosis and monitoring of bladder cancer.
Leyh H; Marberger M; Conort P; Sternberg C; Pansadoro V; Pagano F; Bassi P; Boccon-Gibod L; Ravery V; Treiber U; Ishak L
Eur Urol; 1999 Jan; 35(1):52-6. PubMed ID: 9933795
[TBL] [Abstract][Full Text] [Related]
6. Urinary biomarkers in bladder cancer: A review of the current landscape and future directions.
Ng K; Stenzl A; Sharma A; Vasdev N
Urol Oncol; 2021 Jan; 39(1):41-51. PubMed ID: 32919875
[TBL] [Abstract][Full Text] [Related]
7. Research Progress of Urine Biomarkers in the Diagnosis, Treatment, and Prognosis of Bladder Cancer.
Jin F; Shahid M; Kim J
Adv Exp Med Biol; 2021; 1306():61-80. PubMed ID: 33959906
[TBL] [Abstract][Full Text] [Related]
8. Can urinary biomarkers replace cystoscopy?
Maas M; Bedke J; Stenzl A; Todenhöfer T
World J Urol; 2019 Sep; 37(9):1741-1749. PubMed ID: 30283995
[TBL] [Abstract][Full Text] [Related]
9. Current bladder tumor tests: does their projected utility fulfill clinical necessity?
Lokeshwar VB; Soloway MS
J Urol; 2001 Apr; 165(4):1067-77. PubMed ID: 11257640
[TBL] [Abstract][Full Text] [Related]
10. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
[TBL] [Abstract][Full Text] [Related]
11. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
[TBL] [Abstract][Full Text] [Related]
12. Urinary biomarkers in bladder cancer: where do we stand?
Bhat A; Ritch CR
Curr Opin Urol; 2019 May; 29(3):203-209. PubMed ID: 30855372
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive proteomics and platform validation of urinary biomarkers for bladder cancer diagnosis and staging.
Vanarsa K; Castillo J; Wang L; Lee KH; Pedroza C; Lotan Y; Mohan C
BMC Med; 2023 Apr; 21(1):133. PubMed ID: 37016361
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
15. A comparison of urinary nuclear matrix protein-22 and bladder tumour antigen tests with voided urinary cytology in detecting and following bladder cancer: the prognostic value of false-positive results.
Poulakis V; Witzsch U; De Vries R; Altmannsberger HM; Manyak MJ; Becht E
BJU Int; 2001 Nov; 88(7):692-701. PubMed ID: 11890239
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the clinical value of urinary NMP22 as a marker in the screening and surveillance of transitional cell carcinoma of the urinary bladder.
Chahal R; Darshane A; Browning AJ; Sundaram SK
Eur Urol; 2001 Oct; 40(4):415-20; discussion 421. PubMed ID: 11713396
[TBL] [Abstract][Full Text] [Related]
17. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
[TBL] [Abstract][Full Text] [Related]
18. Comparison of NMP22 BladderChek test and urine cytology for the detection of recurrent bladder cancer.
Kumar A; Kumar R; Gupta NP
Jpn J Clin Oncol; 2006 Mar; 36(3):172-5. PubMed ID: 16520358
[TBL] [Abstract][Full Text] [Related]
19. [Tumor marker tests in bladder cancer].
Feil G; Stenzl A
Actas Urol Esp; 2006 Jan; 30(1):38-45. PubMed ID: 16703728
[TBL] [Abstract][Full Text] [Related]
20. Urine-based biomarkers for the early detection and surveillance of non-muscle invasive bladder cancer.
Herman MP; Svatek RS; Lotan Y; Karakiewizc PI; Shariat SF
Minerva Urol Nefrol; 2008 Dec; 60(4):217-35. PubMed ID: 18923359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
